Ergoloid

Source: Wikipedia, the free encyclopedia.
Ergoloid
beta-Dihydroergocryptine
Ergot alkaloid
Clinical data
Other namesCo-dergocrine, dihydroergotoxine
Pregnancy
category
  • Contraindicated
Routes of
administration		Oral, parenteral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
ECHA InfoCard
100.158.718 Edit this at Wikidata
 ☒NcheckY (what is this?)  (verify)

Ergoloid mesylates (

beta-dihydroergocryptine
).

It was developed by Albert Hofmann (the discoverer of LSD) for Sandoz (now part of Novartis).

Medical uses

It has been used to treat

Alzheimer disease),[1] as well as to aid in recovery after stroke
.

A systematic review published in 1994 found little evidence to support the use of ergoloid mesylates, concluding only that potentially effective doses may be higher than those currently approved in dementia treatment.[2]

Ergoloid Mesylate Tablets USP for sublingual use contain 1 mg of Ergoloid Mesylates USP, a mixture of the methanesulfonate salt of the following hydrogenated alkaloids: Dihydroergocornine mesylate 0.333 mg, Dihydroergocristine mesylate 0.333 mg, Dihydroergocryptine mesylate 0.333 mg.[3]

It has been used to treat

hyperprolactinemia (high prolactin levels).[4]

The use of ergoloid alkaloids for dementia has been surrounded with uncertainties. In 2000, a systematic

Cochrane review concluded that hydergine was well tolerated and showed significant treatment effects when assessed by either global ratings or comprehensive rating scales. The small number of available trials for analysis, however, limited the ability to demonstrate statistically significant moderating effects in certain subgroups (e.g. younger age, higher dosage, Alzheimer disease).[5]

Contraindications

Ergoloid is contraindicated in individuals who have previously shown hypersensitivity to the drug. They are also contraindicated in patients who have psychosis, acute or chronic, regardless of etiology.[6] Specific drug interactions are unknown but it has been claimed that there are multiple potential interactions.[6]

Side effects

Adverse effects are minimal. The most common include transient, dose dependent nausea and gastrointestinal disturbances,[7] and sublingual irritation with SL tablets. Other common side effects include:[6][8]

As a result of the last-mentioned effects, the use of ergoline derivatives for the treatment of blood circulation disorders, memory problems, sensation problems and the treatment of migraine is no longer permitted in some EU countries because the risks are believed to outweigh any benefits.[9] However, this concern may be unnecessarily suppressing the use of ergoline medications.[11]

Pharmacology

Mechanism of action

Despite the fact that this drug has been used in the treatment of dementia for many years, its

catecholamines in the synaptic cleft. In one study, an interaction between age and hydergine treatment was observed in the hypothalamus, hippocampus and cerebellum. The hydergine effect was more pronounced in the aged group in the hypothalamus and cerebellum, and more pronounced in the adult in the hippocampus
. These findings imply that increased brain MAO activity in aging can be modified by hydergine treatment in some brain regions.

Chemistry

The four constituents differ only in which of four proteinogenic amino acids is used in biosynthesis:[15]

Compound Amino acid
Dihydroergocristine Phenylalanine
Dihydroergocornine Valine
alpha-Dihydroergocryptine Leucine
beta-Dihydroergocryptine Isoleucine

Society and culture

Brand names

Brand names include Hydergine, Hydergina, Gerimal, Niloric, Redizork, Alkergot, Cicanol, Redergin, and Hydrine.

References

  1. S2CID 12524454
    .
  2. PMID 8042927
    .
  3. ^ "Ergoloid". Drugs.com. Archived from the original on 12 June 2021. Retrieved 2 August 2013.
  4. S2CID 29368668
    .
  5. PMID 11405961
    .
  6. ^ a b c "Drugs to Treat Alzheimer's Disease". Journal of Psychosocial Nursing & Mental Health Services. 52 (4): 21–22. April 2014.
  7. ^
    PMID 17149427
    .
  8. PMID 24347930
    .
  9. ^ a b "Ergot derivatives: restricted use" (PDF). WHO Drug Information. 27 (3): 225. 2013.[dead link]
  10. S2CID 24802394
    .
  11. S2CID 22768662
    .
  12. PMID 2869188
    .
  13. PMID 10438027
    .
  14. S2CID 35607526
    .
  15. ISBN 3-7692-3483-9
    .

External links